Discussing Herantis’ H1 results with Antti were CEO Antti Vuolanto and Chief Medical Officer Juha Savola 
Topics:
(00:00) Introduction
(00:13) Introduction of the Chief Medical Officer
(02:17) Events of the beginning of the year
(04:31) Cost development
(06:30) Conducted research
(08:59) Phase II study
(10:30) Scope and structure of the study
(13:25) What is the study aiming to answer?
(14:28) The role of the FDA
(16:08) Observations from the industry
(18:18) Focus areas for the rest of the year